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Abstract
Background: Diabetes mellitus (DM) leads to multiple complications, including severe hypoglycaemia events
(SHEs). SHEs can impact a patient’s quality of life and compliance and may directly result in additional costs to the
health care system. The aim of this review was to evaluate the risk of severe hypoglycaemia in patients with type 1
(T1) and 2 (T2) DM as observed in everyday clinical practice for various drug regimens.
Methods: We conducted a systematic review of observational (retrospective or prospective) studies in the
MEDLINE, Embase, and Cochrane Library databases that covered at least 100 children or adults with T1/T2
DM. In T1 DM, basal-bolus/pre-mix insulin (human or analogue) and insulin pump were reviewed, and in T2
DM, basal-bolus/pre-mix insulin (human or analogue), oral antidiabetic drugs supported with basal insulin
(human or analogue), sulfonylureas in monotherapy, and combined oral treatment were reviewed. In order to
estimate SHE rates, we extracted data on the time horizon of the study, number of patients, number of SHEs,
and number of patients experiencing at least one SHE. We used a random effects model to estimate the
annual SHE rate. We considered the risk for other antidiabetic medications in T2 DM to be negligible and the
results of our main review yielded no observational data for premixes in T1 DM so they were assessed based
on relative rates taken from additional systematic reviews. The study, being a desk research, did not involve
any human subjects (including human material or human data) and no ethical committee approval was asked
for. For the same reason there was no need to collect informed consent for participation in the study.
Results: We identified 76 observational studies encompassing 707,722.30 patient-years. The estimated annual
SHE rate varied from 0.168 (95 % CI 0.123–0.237) for insulin pump up to 1.628 for biphasic human insulin in
T1 DM patients, and from 0.0035 for oral antidiabetic drugs up to 0.554 (95 % CI 0.157–7.534) for basal-bolus
with human insulin in T2 DM patients.
Conclusions: Our review indicates that SHE rates differ between patients depending on treatment regimen.
However, SHEs are also driven by other factors. Proper modelling techniques are needed to use various types
of information in published studies.
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Background
Diabetes mellitus (DM) is a common disease with in-
creasing prevalence [1]. DM can lead to microvascular
complications, including retinopathy, nephropathy, and
neuropathy, as well as macrovascular complications
caused mainly by atherosclerotic changes that cause
myocardial infarction, stroke, TIA, and peripheral vascu-
lar disease. Hyperglycaemia is an important patho-
physiological factor in the development of these
complications [2, 3] and key to keeping the glucose con-
centration close to euglycaemic levels in the treatment
of diabetes. This is very challenging in clinical practice
because of the risk of treatment-induced hypoglycaemia.
Hypoglycaemia can be perceived from clinical, physio-
logical, or pathophysiological perspectives through risk
factors and preventive measures. Clinical hypoglycaemia
is described by the Whipple triad [4]. A plasma glucose
concentration < 3.9 mmol/l (<70 mg/dl) with (docu-
mented symptomatic) or without symptoms (asymptom-
atic) is regarded as the threshold for hypoglycaemic
events [5]. A severe hypoglycaemic event (SHE) is de-
fined as one requiring the assistance of another person
to actively administer carbohydrate, glucagon, or other
resuscitative actions. Plasma glucose measurements may
not be available during such an event, but neurological
recovery attributable to the restoration of normal plasma
glucose levels is considered sufficient evidence that the
event was induced by a low plasma glucose concentra-
tion [5]. Severe hypoglycaemia is common in both types
of DM, but less frequent in type 2 (T2). The number of
events depends on many factors, including type, dur-
ation of diabetes, and types of treatment. The event rates
for severe hypoglycaemia in insulin-treated patients as
reported in the literature and expressed as episodes per
100 patient-years range from 62 [3] to 320 [6] in type 1
(T1) DM, and from 0 [7] to 73 [8] in T2 DM.
The objective of this meta-analysis was to assess the
SHE rate in patients with T1 and T2 DM in real life set-
tings for various anti-diabetic treatment regimens. As
data derived from randomized controlled trials (RCTs)
have limited external validity and cannot be used directly
to reflect everyday clinical practice, we decided to focus
on observational studies. One can argue that many con-
founders associated with usual clinical practice are not
appropriately addressed in randomized settings and can
affect the risk of hypoglycaemic events.
The present study is an extension of previously pub-
lished material [9], and here we include additional sys-
tematic reviews from the last 2 years. We also used an
estimation method that is likely closer to actual clinical
mechanisms, i.e., we accounted for some patients having
a bigger risk of SHE and that the events may cluster in a
subgroup of patients. The current review is supple-
mented with two additional systematic reviews targeted
to identify additional studies because some treatment
regimens were not covered by our primary review.
Methods
Main systematic review of observational studies
We conducted a systematic review in the MEDLINE,
Embase, and Cochrane Library databases in stages. The
original search covered observational studies published
between 1 January 2002 and 1 October 2012 and was
last updated 18 September 2014. In all of the updates,
we consistently used the same methodology described in
Online Resource Additional file 1 (and in [9]). Although
the systematic review did not have a registered protocol,
we followed the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [10].
We included both T1 and T2 DM patients (children or
adults) in our analysis. We used a consistent definition
of SHE as an event with low plasma glucose levels that
requires help from another person to manage. This def-
inition has been used in numerous publications [11–15]
and seems to be an attractive and clinically sound choice
for results used in cost-measuring studies because it
directly links SHEs to resource use.
We decided to include observational studies in the
systematic review in order to more accurately assess
SHE rates in real-life settings. Moreover, to account for
changes in clinical practice in recent years and the pos-
sible impact on treatment-related risk, only recent studies
published no more than 10 years ago were included. Tak-
ing into account our updates, the earliest studies could
have been published on 1 January 2002. To balance the
number of studies included and the strength of evidence,
we only included studies of some minimal reasonable size,
which we defined as at least 100 patients in the total study,
though possibly split between several groups.
We designed our review to differentiate between the
following treatment regimens: insulin pumps, basal-
bolus insulin therapy with long-acting insulin analogue
as the basal component (BBA), basal-bolus insulin ther-
apy with human insulin as the basal component (BBH),
biphasic insulin analogue, and biphasic human insulin in
T1 DM, and sulfonylurea (SU) with or without other
oral drugs but excluding insulin, basal long-acting insu-
lin analogue (BOTA), basal human insulin (BOTH),
BBA, BBH, biphasic insulin analogue, and biphasic hu-
man insulin (all insulin regimens could be in combin-
ation with other antidiabetic drugs, OADs) in T2 DM.
We defined basal-bolus insulin therapy as long-acting
insulin analogue once or twice daily and short/ultrashort
insulin at mealtime. In the main systematic review,
OADs in T2 DM, especially oral antidiabetic medica-
tions different than SU, were neglected assuming that
the risk of SHE is negligible. We planned to only assess
risk indirectly using information on relative rates from
Czech et al. BMC Endocrine Disorders  (2015) 15:57 Page 2 of 14
studies searched for in a separate systematic review of
secondary studies as described below.
Two authors independently conducted the selection
process for relevant trials (basic search: J.P. and E.R.; 1st
update: J.P. and E.R.; 2nd update: E.R. and M.J.). Protocol
assumed that in the case of discrepancies between the
authors, a discussion would be held until consensus was
reached. We extracted the following parameters: time
horizon at which hypoglycaemia was assessed, number
of patients in the study group, number of hypoglycaemic
episodes (absolute or mean per patient in a specified
period of time, if available), and number of patients ex-
periencing at least one SHE (if available). If one study
was described in more than one manuscript, then the
manuscript with the most appropriate and complete re-
sults was selected for extraction (e.g., data for a total
study cohort instead of subpopulation, results presented
separately for patients with T1 and T2 diabetes, or re-
sults split by insulin regimens of interest). Data from in-
cluded studies were extracted by one of the reviewers
and verified by the other.
We assessed the quality of the observational studies
using the Newcastle-Ottawa Scale (NOS) [16], a tool de-
veloped for case–control and cohort studies that allows
the quality of non-randomized studies (its design, con-
tent, and ease of use) to be assessed. Deeks et al. [17]
pointed out that this scale is one of the two best for
evaluating non-randomized interventional studies and
can be used in systematic reviews as either a scale or a
checklist. This tool is also mentioned in the Cochrane
Handbook as a tool that can be used for assessing meth-
odological quality or risk of bias in non-randomized
studies [18]. Thus, in our systematic review we decided
to use NOS for case–control and cohort studies, while
in order to assess the quality of other types of non-
interventional studies we focused on the following ele-
ments: patient selection methods, methods for recording
outcomes (regarding only severe hypoglycaemia), study
size, and study representativeness. According to a recent
systematic review of tools used to assess the quality of
observational studies [19], there are 97 tools (46 scales
and 51 checklists) that can be used to evaluate observa-
tional studies, but a transparent objective assessment of
the quality of observational research is still missing.
As it was a desk research, the study did not involve
any human subjects (including human material or hu-
man data) and no ethical committee approval was asked
for. For the same reason there was no need to collect in-
formed consent for participation in the study.
Supplementary systematic reviews
As mentioned above, we planned to assess the risk related
to OADs in T2 DM by calculating the relative rates com-
pared to SU based on secondary studies and then impose
these relative rates on the background SU-related SHE
rate. Our main systematic review also yielded no observa-
tional studies for biphasic therapies in T1 DM; therefore,
we decided to use similar methodology to assess the SHE
rate for that treatment regimen.
In the first of the two additional systematic reviews we
used the following approach. We searched MEDLINE,
Embase, the Cochrane Library, and Centre for Reviews
and Dissemination (CRD) to identify secondary studies
(systematic reviews and meta-analyses) that can be used
to estimate the relative rates (see search strategy in
Additional file 1). Studies were included if the search
was performed in at least two databases, including at
least one of the above databases, by at least two authors
(due to the need to confirm the search results) and if the
search strategy was described. RCTs of T2 DM required
at least one of the following: dipeptidyl peptidase-4 in-
hibitor, glucagon-like peptide-1 agonist, OADs such as
metformin, and TZD. In addition, severe hypoglycaemia
had to be defined as an episode when a patient required
help from another person. We used RCTs instead of ob-
servational studies because they more commonly pro-
vide data on relative rates.
We used the following approach in the second of the
additional reviews. The MEDLINE database was searched
on 25 February 2015 using the search strategy presented
in Additional file 1. Only systematic reviews and RCTs
(also those included in systematic reviews) were eligible.
Studies performed in patients with T1 DM or T1 and T2
DM (with results presented separately) had to compare
patients randomized to a group receiving biphasic insulin
analogues to a group receiving biphasic human insulin, a
group receiving a basal-bolus insulin regimen, or a group
on insulin pumps.
Data synthesis methods for the main review
The data from included studies vary in structure, i.e.,
some studies present the total number of episodes in
a given group of patients over some time horizon,
whereas others present the number of patients who
experienced at least one event, and some studies present
both. Studies also differ with respect to time horizon. In
order to increase the flexibility of the model, we chose the
Bayesian approach using the Markov Chain Monte Carlo
(MCMC) estimation method implemented in JAGS using
R.
We based our model on negative binomial distribution
for the following reasons. Firstly, in the previous analysis
we used the Poisson distribution as a natural choice to
model count data that were available [9]. However, in
the present paper we decided to account for the fact that
episodes tend to be concentrated in a subgroup of pa-
tients; in most of the studies, we observed that fewer pa-
tients actually experienced any episode than suggested
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by a Poisson distribution for a given total number of ob-
served episodes. This observation may stem from some
individual predispositions (e.g., lifestyle, genetics, etc.)
and would require the introduction of a zero-inflation
mechanism, i.e., the fact that many patients will have no
events but some will tend to have multiple events.
Secondly, we did not have access to individual patient
data (i.e., we only observed the total number of episodes
in a study); thus, we needed to work with a distribution
that can be aggregated to describe the number of epi-
sodes in a cohort. We also needed to be able to account
for varying time horizons under plausible assumptions.
Thirdly, we wanted the results of the estimation to be
easily usable in further modelling, and we did not want
the SHE rates to vary over time, which would require
knowing the longevity of the treatment, even assuming
that the time to first SHE is distributed differently than
the time to subsequent SHEs and would be a possible
way of introducing the zero-inflation phenomenon.
The negative binomial distribution allows for a cluster-
ing effect and can be easily mathematically expressed for
groups of patients observed for varying time horizons.
We decided to use a mixed fixed-effect and random-
effect approach by assuming that the parameter measur-
ing the over-dispersion is fixed across studies for a given
treatment regimen while the other parameter impacting
the absolute rate was random. This approach allows us
to account for heterogeneity between studies, whereas
taking both parameters in the random-effect approach
yielded unstable results. Non-informative prior distribu-
tions were taken.
The specification and JAGS codes are given in the sup-
plementary material (Additional file 2).
As studies usually have only one arm, the SHE rate is
estimated separately for the individual classes of drugs.
Importantly, the aim of the present study was not to
compare drugs, which requires two-arm studies, possibly
with randomization, but rather to estimate the absolute
rate of SHEs for all of the drug classes separately, ac-
counting for the tendency to prescribe various drugs to
patients with varying baseline risks of SHEs (e.g., life-
style) in clinical practice.
The median values of posterior distributions were used
as point estimates. The 2.5 and 97.5 percentiles were used
as limits of 95 % confidence intervals (CIs). We used
10,000 iterations as a burn-in phase and then collected
every fifth of 50,000 iterations. The estimated parameters
of the model allow us to assess the SHE rate (i.e., average
number of events per patient-year) and the probability of
a given patient suffering at least one SHE over a year.
Data synthesis methods for the relative rates
Data used for the estimation of relative rates from identi-
fied studies were provided in terms of 2×2 tables including
the number of SHEs and person-time calculated by multi-
plying a number of patients and a time horizon for each
group. Data given in such a format can be aggregated
using the Mantel-Haenszel method, which does not re-
quire calculating the value of individual outcomes.
In order to estimate relative rates based on RCTs we
used the ‘metafor’ and ‘lme4’ libraries available in R soft-
ware to estimate the incidence relative rate (IRR) when
information on the number of episodes was available.
We synthesized data using the rma.mh function available
in the ‘metafor’ package. This function fits fixed-effects
models to a 2×2 table and person-time data via the
Mantel-Haenszel method, which is based on a weighted
estimation approach. Zero events are not a problem in
this method unless there are no events for one of the
two groups. In such cases it is necessary to add a con-
stant (e.g., 0.5) to the number of events [20].
Results
Systematic review of observational studies
As mentioned previously, we conducted the systematic
review in three stages. The basic literature search yielded
6214 records, and after duplicate removal 5220 articles
were assessed by titles and abstracts. We reviewed 526
full texts, 101 of which [6, 21–120] met the inclusion
criteria. A total of 55 individual trials were eligible for
the analysis. The details of trial identification are given
in Additional file 3, and the characteristics of included
studies are given in Additional file 4.
For T1 DM we included 21 studies described in 33 ar-
ticles. Among these studies, 14 provided data on SHEs
in patients on insulin pumps (6714.61 patient-years
total), 7 on BBA (9656.18 patient-years in total), and 6
on BBH (2881.57 patient-years total). As mentioned pre-
viously, we did not find any studies on treatment with
biphasic insulin in T1 DM and we carried out a supple-
mentary search for studies on pre-mixed insulin (details
are given below). For T2 DM we included 35 studies de-
scribed in 76 articles. Among these studies, 11 provided
data on basal long-acting insulin analogue ± OADs
(5347.87 patient-years total), 7 on basal human insulin ±
OADs (2142.13 patient-years total), 6 on BBA ±OADs
(1456.05 patient-years total), 3 on BBH ±OADs (227.46
patient-years total), 12 on biphasic insulin analogue ±
OADs (48,168.49 patient-years in total), 6 on biphasic
human insulin ± OADs (2265.87 patient-years total), and
6 on SU ±OADs but excluding insulin (1776.00 patient-
years total).
The first update of the basic search resulted in 409 re-
cords, which were screened by title and abstract, and
duplication removal resulted in 31 new full publications.
A total of five articles [121–125] met the inclusion cri-
teria, three of them describing new studies. All identified
articles provided data for patients with T2 DM. Three
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publications presented data on biphasic insulin analogue ±
OADs (2501.16 patient-years total), two on BOTA (8084.27
patient-years total), and one on biphasic human insulin ±
OADs (505.84 patient-years total). The details of trial
identification and the characteristics of included studies are
given in Additional files 3 and 4, respectively.
The second update yielded 1727 records (1509 after
duplication removal), which were assessed by titles and
abstracts. We reviewed 318 full texts, from which 58
manuscripts describing 24 individual trials (18 new stud-
ies) [126–183] were eligible for the systematic review.
The details of trial identification are given in Additional
file 3. The characteristics of included studies are given in
Additional file 4.
For T1 DM we included eight studies (seven new stud-
ies) described in eight articles, six of them provided data
on SHEs in patients on insulin pumps (828.97 patient-
years total) and one on BBA (99,804.50 patient-years
total) and BBH (72,697.25 patient-years total). The re-
sults from one of the identified publications are not in-
cluded in the systematic review because we previously
identified and used another manuscript that presented
results on the same patient population.
For T2 DM we included 18 studies (12 new studies)
described in 53 manuscripts. Among these studies, six
provided data on BOTA (1367.50 patient-years total),
one on BOTH (332,525.00 patient-years total), four on
BBA (106,938.75 patient-years total), one on biphasic in-
sulin analogue ± OADs (124.20 patient-years total), one
on biphasic human insulin ± OADs (119.25 patient-years
total), and four on SU (1589.39 patient-years total). Re-
sults from the other publications were not used because
they presented data on populations already assessed in
articles identified in previous searches.
We assessed the quality of the studies using the
Newcastle-Ottawa Scale (NOS) [16] for case–control
and cohort studies. Other types of observation studies
were assessed by focusing on four aspects: i) patient se-
lection methods, ii) methods of recording outcomes re-
garding severe hypoglycaemia, iii) study size, and iv)
study representativeness. Generally, the quality of the
studies varied. Among the identified case–control studies,
only one scored 5 out of 9 points; other studies were of
lower quality: three scored 2 points, three scored 3 points,
and two scored 4 points. Among cohort studies, three
scored 8 of 9 possible points; other studies were of lower
quality: one scored 5 points, eight scored 6 points, and six
scored 7 points. The residual studies were of medium
quality as assessed by descriptions with no scoring.
Additional systematic reviews
In order to estimate the expected annual number of
SHEs related to OADs (mainly oral) in T2 DM we per-
formed an additional systematic review. This search
resulted in a total of 958 potentially relevant publica-
tions, which were assessed by titles and abstracts. After
duplicate removal, 215 full publications were evaluated,
from which 12 systematic reviews fulfilling predefined
inclusion criteria were identified (Additional file 3). Of
the included systematic reviews, a study conducted by
Karagiannis et al. [184] was assessed to provide the most
appropriate data on SHEs associated with various antidi-
abetic medications in T2 DM. We reviewed all studies
included in Karagiannis et al. [184] in order to obtain
the number of SHEs in each of them. We also verified
the definition of severe hypoglycaemia; if it did not com-
ply with the definition assumed for our systematic re-
view, the results from the study were excluded. A total
of 11 RCTs [185–195] were identified and included in
the analysis.
Our main systematic review yielded no observational
studies for biphasic therapies in T1 DM; therefore, we
performed an additional systematic review. A total of
454 records were assessed by titles and abstracts, among
which 24 full publications were evaluated and 12 met
the inclusion criteria. An additional two publications
were identified from the references (Additional file 3). A
total of seven systematic reviews described five relevant
RCTs (see Additional file 3) [196–209]. These studies
were then used to assess the relative risk for biphasic
therapies in T1 DM.
SHE rates for treatments based on the main review
The information on the number of SHEs in individual
studies is presented in Additional file 5.
The results of the data synthesis are presented in
Table 1.
SHE rates for treatments based on supplementary reviews
Because the results indicated no significant difference
between basal human insulin in a basal-bolus regimen
and biphasic insulin analogues (IRRFE = 0.5000, 95 % CI
0.1250–1.992) and the confidence interval is very wide,
we assumed that these two treatments are related to an
identical SHE rate. The difference between biphasic hu-
man insulin and biphasic insulin analogue (IRRFE =
1.5015, 95 % CI 0.9571–2.3558) was also not significant,
but the 95 % CI clearly moved towards values >1. The
direction agreed with a general tendency of human insu-
lin being related to a greater SHE rate in T2 DM; thus,
we used the point estimate to correct the SHE rate com-
pared to biphasic insulin analogue.
For OADs, i.e., metformin, DPP-4, GLP-1, and TZD,
the risk of SHEs relative to SU were assessed using data
from a previously identified systematic review [184] and
referred the risk of SHEs for SU estimated in our sys-
tematic review of observational studies. The estimated
relative rate for DPP-4 inhibitors and SU was 0.0783
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(95 % CI 0.0284–0.2161). There was no significant differ-
ence in the risk rate between other OADs and GLP-1.
Thus, we applied the relative rate to correct the SHE
rate estimated for SU and use it for OADs.
The results are presented in Table 2. Because the aver-
age rates of SHE in this case are only based on indirect
reasoning, we present no CI and assessed no probability
of at least one event.
Discussion
Data
In this review, we attempted to assess the real-life risk of
SHEs associated with various drug regimens. Data selec-
tion was constructed to best fit this goal. Because we
wanted to assess risk in everyday clinical practice rather
than an experimental setting, we decided to use observa-
tional studies and not RCTs. Moreover, many factors can
change over time, such as clinical practice in treating
DM, patient awareness, and lifestyle. Therefore, we de-
cided to focus only on newer studies. As our systematic
review was performed in three waves, our data selection
encompassed the period starting 1 January 2002 and
lasted no more than 13 years. We decided to disregard
small studies, assuming that they would contribute little
to the total information and that a smaller study size
could potentially be associated with lower quality. Im-
portantly, these decisions were made to fit the body of
evidence to the goal of the study.
Not surprisingly, using observational studies resulted in
significant heterogeneity, which we tried to reduce with a
consistent definition of SHEs. We decided to use a defin-
ition that relates this event to resource consumption, as it
makes the results of our study useful in subsequent eco-
nomic evaluations. As much as the heterogeneity poses
quantitative difficulties, it is unavoidable because the
population of diabetic patients is heterogeneous when we
account for treatment duration, compliance, and lifestyle,
among other factors, which may result in very different
risks of hypoglycaemia. In this sense it would be naïve to
expect homogeneous results. This heterogeneity has been
widely observed in published studies of different sizes and
designs [3, 6–8]. In order to account for the heterogeneity
we used a (partially) random-effect model, and the hetero-
geneity results in wide confidence intervals, which should
simply be treated as an unavoidable price to pay.
We also tried to limit the impact of heterogeneity by
splitting the drugs into treatment groups that seem to
be clinically related to various SHE rates. The difficulty
is that we can expect reverse feedback, i.e., patients with
a high risk of hypoglycaemia may use drugs that cause
hypoglycaemia less often, and the net effect may be
weakened or even reversed.
We considered performing a meta-regression but ul-
timately decided that the number of studies is too small
for most of the treatment regimens. Furthermore, our
goal was not to understand other factors impacting the
risk of SHEs, but to construct a set of parameters relat-
ing the risk to treatment groups used in clinical practice.
Table 1 Annual mean (95 % CI) number of SHEs in patients with T1 and T2 DM
Therapy Average number of SHEs per patient per year Probability of ≥1 SHE for a patient annually
T1
Insulin pump 0.168 (0.123–0.237) 11.38 % (8.09 %–16.03 %)
Basal-bolus (basal insulin analogue) 0.472 (0.252–1.055) 21.37 % (11.30 %–42.97 %)
Basal-bolus (basal human insulin) 1.084 (0.530–2.900) 33.77 % (17.93 %–67.53 %)
T2
BOT analogue 0.113 (0.050–0.324) 5.55 % (2.32 %–15.62 %)
BOT human 0.173 (0.072–0.600) 7.95 % (3.18 %–26.35 %)
Basal-bolus (basal insulin analogue) 0.080 (0.027–0.456) 4.78 % (1.21 %–27.04 %)
Basal-bolus (basal human insulin) 0.554 (0.157–7.534) 31.40 % (7.44 %–99.64 %)
Pre-mix insulin analogue 0.092 (0.052–0.186) 6.23 % (3.41 %–12.49 %)
Pre-mix human insulin 0.299 (0.137–0.868) 12.43 % (5.87 %–31.85 %)
Sulfonylureas 0.045 (0.023–0.115) 3.57 % (1.91 %–7.56 %)
BOT Basal therapy combined with oral antidiabetic medication, SHE Severe hypoglycaemia event, T1, T2 DM Type 1, Type 2 diabetes mellitus
Table 2 Annual mean number of SHEs in patients with T1
and T2 DM
Therapy Average number of SHEs per patient per year
T1
Pre-mix insulin analogue 1.084
Pre-mix human insulin 1.628
T2
OADs (excl. SU) 0.0035
OADs Other antidiabetic drugs, SHE Severe hypoglycaemia event,
SU Sulfonylurea, T1, T2 DM Type 1, Type 2 diabetes mellitus
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Applying more complex models in subsequent studies
aiming to assess the number/burden of SHEs in some
populations would be more difficult because it would re-
quire knowing the values of other explanatory variables
to input them in the model.
Some of the inclusion criteria help reduce hetero-
geneity. Using newer studies helps us focus on mech-
anisms that most likely prevail in present clinical
practice. Using larger studies reduces randomness. Ex-
cluding studies comes at the cost of making the body
of evidence small, but we ultimately decided that this
compromise is worthwhile.
The included observational studies were generally
case-control and cohort studies of medium and good
quality, respectively, indirectly due to the use of the
NOS [16], which can be applied only to these two types
of studies. However, the majority of included studies
could not be classified to either group and were assessed
by descriptions with no scoring; the results suggest that
they are also of medium quality. According to Shamliyan
et al. [19] there are 97 tools (46 scales and 51 checklists)
that can be used to evaluate observational studies, but
transparent objective assessments of the quality of obser-
vational research are missing. We decided to use NOS
because it is one of the two best and recommended tools
to evaluate non-randomized interventional studies [17].
Ultimately, we had to use different types of studies to as-
sess the risk of OADs in T2 DM and biphasic insulin in
T1 DM. The former was part of the methodology assumed
from the very beginning and resulted from our conviction
that the risk associated with OADs is so small that any
possible errors will be small in absolute terms; the latter
resulted from the limited availability of observational data.
Using data from RCTs violates our general methodology.
Also, taking into account the lack of significance in both
comparisons for biphasic insulin in T1 DM, other quanti-
tative estimation approaches could be used. This part of
our results should be treated with caution, but we still
wanted to end up with a set of parameters.
Methodology
As mentioned above, the present research is an update
of a previously published systematic review [9]. We
think that the data synthesis was markedly improved in
the present version. Using the binomial distribution
allowed us to take into consideration that some patients
may have greater risk of hypoglycaemia than others and
that the events may cluster in some patients, but this
distribution does not force this clustering. Estimation
results confirm that this is the case, i.e., the estimated
parameters show that this phenomenon occurs. For ex-
ample, for insulin pumps in T1 DM, the average annual
number of SHEs is 0.168. Assuming that a Poisson dis-
tribution governs the number of episodes in individual
patients, we would conclude that 15.5 % have at least
one event per year. Using the negative binomial distribu-
tion allows us to estimate this parameter separately,
yielding 11.4 % instead.
Different approaches have been suggested and were
tested by us. For example, a two-step model could be
constructed in which a patient is randomly determined
to not have any or to have at least one SHE, and then
the actual number of SHEs is randomly determined. An
alternative method is assuming that the time to the first
SHE is distributed differently than the time to the subse-
quent SHEs. Such approaches would result in more
complicated modelling, and it may be difficult to specify
the model with no individual patient data and to subse-
quently use it because it would require knowing the
treatment history and information on past SHEs.
Using the negative binomial distribution allows us
to account for (but not enforce) the clustering effect
and to estimate two parameters of interest: the annual
number of events and the risk of experiencing at least
one event. The former may be more useful in subse-
quent economic studies. The latter may be important
when analysing the fear of hypoglycaemia attributed
to individual treatment regimens.
Results
From a clinical perspective the results are consistent
with the general overview of treatment regimens and as-
sociated risk of SHEs. We generally observed that the
risk of SHEs is higher for T1 DM than T2 DM and
mainly attributable to insulin injections; SU-based oral
antidiabetic treatments were found to be related to the
lowest risk of SHEs. Insulin analogues are related to a
much smaller risk than human insulin, especially in
basal-bolus therapy in T2 DM, and pre-mixes and BOTs
seem to be related to a reduced risk compared to more
intensive treatment with basal-bolus of human insulin
(in T2 DM), but not for insulin analogues. The only one
striking, but not unexpected, finding is the difference in
SHE risk for insulin analogue and human insulin com-
ponents of basal-bolus therapy in T2 DM. One could
argue that we were not able to fully control for diabetes
duration and other cofounders, which results in a much
higher risk of SHEs attributable to human insulin.
Nevertheless, the main and most valuable finding of our
study is the quantitative estimation of consistently de-
fined and reported SHE risk related to the most com-
mon treatment regimen rather than individual drugs.
Limitations
This study obviously has numerous limitations. We
consider the heterogeneity of the studies to be the most
important limitation. Even though heterogeneity was to
be expected and is unavoidable, it results in wide
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confidence intervals; thus, the actual rates may be sub-
stantially different than our point estimates. For some
treatment groups there were only a few studies, and they
may mistakenly present the overall true picture. Never-
theless, the current results try to use the best currently
available data.
It is important to correctly perceive the applicability of
our results. We did not aim to compare therapies so as
to draw interventional conclusions, i.e., so as to con-
clude about the effect of prescribing this drug instead of
another on the risk of SHEs. Because we, in principle,
did not use multi-arm studies or randomized trials, that
kind of conclusions are not authorized. Thus, there
are limitations with respect to the types of questions
answered by our study.
Notably, we focussed only on one element related to
the risk of hypoglycaemia, but there are many more. We
do not claim that the therapy used is the most important
determinant of SHE risk. However, this factor can be
relatively well quantified and measured and subsequently
used to try to estimate the number of SHEs more
precisely using strata.
Relevance to previous research
We performed a simple search in the MEDLINE database
to determine if there are other systematic reviews or
meta-analyses that evaluate real-life risk of severe
hypoglycaemia among patients with T1 and T2 DM for
various therapies. We used the search terms “severe”,
“major”, “serious”, “hypoglycaemia”, “diabetes”, “observa-
tional”, and “real life” to identify potentially relevant cita-
tions. We did not find other systematic reviews or meta-
analyses that assessed average annual rates of SHEs associ-
ated with various insulin regimens and OADs based on
observational studies.
A review by Bolen et al. [210] was closest to ours; the
aim of their study was to summarize the English lan-
guage literature on the benefits and harms of oral agents
in adult patients with T2 DM. Bolen et al. identified two
systematic reviews and 216 controlled trials and cohort
studies. All systematic reviews and 167 trials evaluated
adverse events, 67 % of which were RCTs and the rest
observational. Bolen et al. used a random-effect model
to estimate post-treatment differences in absolute risk
for adverse events between individual drugs, drug
groups, or therapies. Bolen et al. combined results for
minor and major hypoglycaemia, whereas our aim was
only to estimate the average annual rate of severe
hypoglycaemia. The previous review also did not provide
a definition of major hypoglycaemia; Bolen et al. [210]
conducted a meta-analysis indicating that the use of sec-
ond generation SU results in a higher frequency of
minor and major hypoglycaemia episodes than therapy
with metformin or TZD. This trend is in line with our
analysis of data from RCTs included in Karagiannis et
al., that SU drugs are associated with a higher risk of
hypoglycaemia than OADs [184].
Another meta-analysis of observational studies was
conducted by Goto et al. [211]. This review evaluated an
association between severe hypoglycaemia and the risk
of cardiovascular disease in patients with T2 DM based
on cohort studies and RCTs, as long as an observational
analysis of the analysed association was available. That
meta-analysis included six studies: two secondary analyses
of RCTs and four based on administrative databases.
However, neither of those analyses fulfilled the inclusion
criteria of our systematic review due to an inappropriate
definition of severe hypoglycaemia. Goto et al. [211] used
relative risk as a measure of effect to estimate the associ-
ation between SHEs and cardiovascular disease. Their
findings suggest that severe hypoglycaemia is associated
with approximately twice the risk of cardiovascular disease
and indicate that an evaluation and quantification of the
risk of severe hypoglycaemia is needed.
Conclusions
Various drug regimens differ in terms of the risk of se-
vere hypoglycaemia and our results are consistent with
the general perception of a higher risk of hypoglycaemia
being associated with T1 DM compared to T2 DM,
insulin-based treatment versus oral antidiabetic drugs,
and human insulin versus analogues. Observational
studies seem to be well suited for assessing the real-life
risk, but they increase the heterogeneity of data. A nega-
tive binomial distribution can be used to model various
forms of data and allows us to account for clustering,
which is an expected clinical phenomena confirmed by
our results. The results of our studies can be used to
provide parameters for cost-of-illness studies estimating
the overall burden of hypoglycaemia.
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